Speakers

Amara Okafor runs a cardiometabolic risk clinic and sits on the guideline committee that revised the regional lipid targets last year.

Daniel Reyes leads the statistics group of a multi-site trials unit and has designed four adaptive platform trials across oncology and critical care.

Elena Rossi’s group develops manufacturing processes for engineered T-cell therapies and runs the institute’s first-in-human programme.

Fatima Al-Sayed leads antimicrobial stewardship at a children’s hospital and coordinates a regional respiratory virus surveillance network.

Hiroshi Sato leads a registry-linked real-world evidence programme whose studies have supported two label extensions.

Kwame Mensah advises payers and manufacturers on the evidence needed to price and reimburse advanced therapies.

Liam O’Connell built the pre-emptive pharmacogenomic testing service now used across three teaching hospitals.

Mei Chen leads single-cell profiling for a national immune atlas and works on translating its reference maps into diagnostic panels.

Priya Raman splits her time between a breast oncology clinic and a laboratory studying circulating tumour DNA as a guide to therapy decisions.

Rachel Goldberg spent a decade as a regulatory reviewer before advising sponsors on trial designs regulators will accept.

Sarah Whitfield set up a network of nurse-led clinics for heart failure and diabetes and now trains the practitioners who staff them.

Tomasz Nowak develops validated digital endpoints from wearable sensor data for decentralised clinical trials.